Humacyte, Inc. (HUMA) has a MoatMap StockRank of 0/100 based on Quality (15/100), Value (29/100), and Momentum (12/100) factor scores. The current signal is STRONG SELL. Humacyte, Inc. is another small-cap US healthcare (biotech) company ($191M MCap) with an extremely low SmartRank (SR: 0.2), poor quality (Q:13), and a 'STRONG_SELL' signal. As with Genelux, this type of early-stage, speculative biotech company does not align with the fund's philosophy of investing in 'quality compounders' with durable moats and predictable reinvestment runways. There is no identified macro tailwind to offset the inherent risks.